New
HealthMore in Health→
Supreme Court Ruling Backs Hikma in Skinny-Label Case
The US Supreme Court unanimously ruled that Hikma did not infringe Amarin patents, a decision with implications for skinny-label generic drug disputes.
Key Takeaways
- The Supreme Court unanimously ruled in favor of Hikma Pharmaceutical.
- The case concerns patent claims tied to so-called skinny labeling.
DE
DT Editorial Team··via statnews.com